Biotech entity
Every one of those 1 sits in a single category, acquisition. Novartis AG is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 8, the average consequence score sits above the same-window beat average of 6.4.
Last mentioned: Mar 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, acquisition. Novartis AG is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 8, the average consequence score sits above the same-window beat average of 6.4. Source depth averages 3 original sources per story, versus 2.8 across the same-window beat baseline. We currently track 1 Biotech story that mention SNV4818, all published on March 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering SNV4818. Shared-story counts are live from our verified record — not editorial picks.
Pipeline Integration
Expected completion of the asset transfer and full integration into Novartis's global oncology pipeline.
Acquisition Announcement
Novartis announces the acquisition of SNV4818 for a total deal value of up to $3 billion.
Synnovation Development
Synnovation Therapeutics advances SNV4818 through early clinical stages, showing promising medicinal chemistry results.
Novartis Spin-off
Novartis completes the spin-off of its Sandoz generics division to focus exclusively on innovative medicines.
Novartis AG has entered into an agreement to acquire SNV4818, an experimental breast cancer drug from Synnovation Therapeutics, in a deal valued at up to $3 billion. This strategic move aims to strengthen Novartis's leadership in the oncology sector as it seeks to replenish its pipeline with high-potential targeted therapies.
SNV4818 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
